Topical dexamethasoneγ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema

Diabetic macular oedema is still a significant cause of vision drop in the diabetic patient with no definitive regime for treatment. This study was on the result of effects of intravitreal injection of (2mg) triamcinolone on central macular thickness measured by OCT, visual acuity and intraocular pressure in pseudophakic eyes with diabetic macular oedema as a primary treatment line followed in six months. This study is a prospective, interventional case study series. It was on patients who received intravitreal injection of Triamcinolone in a single dose of ( 2 mg/0. 05 ml). Central macular thickness by OCT, visual acuity, and intraocular pressure was measured pre-injection and 1,3,6 months after injection. This study was performed in Iraq, Baghdad, Ibn Al-Haitham Teaching Eye Hospital from October 2014 to July 2015. Results showed 25 eyes received intravitreal injection of Triamcinolone Acetoniod with pre-injection central macular thickness 597.9+98.02 µm, visual acuity 1.096+0.61 Log MAR and intraocular pressure of 16.5+ 2.53 mmHg. After six months of follow up on central macular thickness 341.6+163.1 µm, visual acuity was 0.63 + 0.40 Log MAR and IOP was 18. 04+ 5. 63mmHg. This study suggests that intravitreal injection of Triamcinolone in a dose 2mg / 0. 05ml improves both anatomical and visual outcome in 21 eyes (84%) out of 25 pseudophakic eyes with diabetic macular oedema during first six months after injection and an increase in intraocular pressure in 2 eyes (8%). The intraocular pressure was despite the use of anti-glaucoma medications during this period.

Download Full-text

Visual acuity and central macular thickness comparison between posterior sub-Tenon's capsule triamcinolone injection and vitrectomy for diffuse diabetic macular oedema

Acta Ophthalmologica ◽

10.1111/j.1755-3768.2012.s036.x ◽

2012 ◽

Vol 90 ◽

pp. 0-0

Author(s):

S NONOMURA ◽

T OSHITARI ◽

S YAMAMOTO

Keyword(s):

Visual Acuity ◽

Macular Oedema ◽

Diabetic Macular Oedema ◽

Macular Thickness ◽

Central Macular Thickness ◽

Tenon’S Capsule ◽

Triamcinolone Injection ◽

Tenon's Capsule

Download Full-text

Improved visual acuity and macular thickness 1 week after intravitreal triamcinolone for diabetic macular oedema

Eye ◽

10.1038/sj.eye.6701766 ◽

2004 ◽

Vol 19 (12) ◽

pp. 1325-1327 ◽

Cited By ~ 3

Author(s):

M S Islam ◽

A Negi ◽

S A Vernon

Keyword(s):

Visual Acuity ◽

Macular Oedema ◽

Diabetic Macular Oedema ◽

Macular Thickness ◽

Intravitreal Triamcinolone

Download Full-text

One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab

European Journal of Ophthalmology ◽

10.1177/1120672120927275 ◽

2020 ◽

pp. 112067212092727

Author(s):

Marko Lukic ◽

Gwyn Williams ◽

Zaid Shalchi ◽

Praveen J Patel ◽

Philip G Hykin ◽

...

Keyword(s):

Visual Acuity ◽

Diabetic Retinopathy ◽

Early Treatment ◽

Macular Oedema ◽

Real Life ◽

Diabetic Macular Oedema ◽

Foveal Thickness ◽

Macular Volume ◽

Central Foveal Thickness ◽

The Mean

Purpose To assess visual and optical coherence tomography–derived anatomical outcomes of treatment with intravitreal aflibercept (Eylea®) for diabetic macular oedema in patients switched from intravitreal ranibizumab (Lucentis®). Design Retrospective, cohort study. Participants Ninety eyes (of 67 patients) receiving intravitreal anti–vascular endothelial growth factor therapy were included. Methods This is a retrospective, real-life, cohort study. Each patient had visual acuity measurements and optical coherence tomography scans performed at baseline and 12 months after the first injection of aflibercept was given. Main Outcome Measures We measured visual acuities in Early Treatment Diabetic Retinopathy Study letters, central foveal thickness and macular volume at baseline and at 12 months after the first aflibercept injection was given. Results Ninety switched eyes were included in this study. The mean (standard deviation) visual acuity was 63 (15.78) Early Treatment Diabetic Retinopathy Study letters. At baseline, the mean (standard deviation) central foveal thickness was 417.7 (158.4) μm and the mean macular volume was 9.96 (2.44) mm3. Mean change in visual acuity was +4 Early Treatment Diabetic Retinopathy Study letters (p = 0.0053). The mean change in macular volume was −1.53 mm 3 in SW group (p = 0.21), while the change in central foveal thickness was −136.8 μm (p = 0.69). Conclusion There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.

Download Full-text

Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy

Scientific Reports ◽

10.1038/s41598-021-84553-7 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Chu-Hsuan Huang ◽

Chang-Hao Yang ◽

Yi-Ting Hsieh ◽

Chung-May Yang ◽

Tzyy-Chang Ho ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Visual Acuity ◽

Growth Factor ◽

Treatment Response ◽

Macular Oedema ◽

Diabetic Macular Oedema ◽

Vascular Endothelial ◽

Outer Retina ◽

Hyperreflective Foci ◽

Endothelial Growth Factor

AbstractThis retrospective study evaluated the association of hyperreflective foci (HRF) with treatment response in diabetic macular oedema (DME) after anti-vascular endothelial growth factor (VEGF) therapy. The medical records, including of ophthalmologic examinations and optical coherence tomography (OCT) images, of 106 patients with DME treated with either intravitreal ranibizumab or aflibercept were reviewed. The correlations between best-corrected visual acuity (BCVA) changes and HRF along with other OCT biomarkers were analysed. The mean logMAR BCVA improved from 0.696 to 0.461 after an average of 6.2 injections in 1 year under real-world conditions. Greater visual-acuity gain was noted in patients with a greater number of HRF in the outer retina at baseline (p = 0.037), along with other factors such as poor baseline vision (p < 0.001), absence of epiretinal membrane (p = 0.048), and presence of subretinal fluid at baseline (p = 0.001). The number of HRF after treatment was correlated with the presence of hard exudate (p < 0.001) and baseline haemoglobin A1C (p = 0.001). Patients with proliferative diabetic retinopathy had greater HRF reduction after treatment (p = 0.018). The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment.

Download Full-text